ClinicalTrials.gg
RecruitingNCT06797206MATRIARCH_CFUpdated Oct 1, 2025

A Study of Females With CF Throughout Pregnancy and Post-partum, and Follow up of Their Offspring

An observational study in Cystic Fibrosis (CF), Pregnancy and Infant, Newborn, sponsored by Royal Brompton & Harefield NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by Royal Brompton & Harefield NHS Foundation Trust · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Cystic Fibrosis by Royal Brompton & Harefield NHS Foundation Trust — 3 open to participants now, 4 under way, none of them phase 3. Cystic Fibrosis · Royal Brompton & Harefield NHS Foundation Trust.

Started
2025
the only one that year
Observational
5 of 16
2 open now
Registered
14th of 16
by date

Among the 16 studies in Cystic Fibrosis by Royal Brompton & Harefield NHS Foundation Trust, this one is the only one that started in 2025, is one of 5 observational ones, and was the 14th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

3 of the 16 studies in Cystic Fibrosis by Royal Brompton & Harefield NHS Foundation Trust are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Cystic Fibrosis by Royal Brompton & Harefield NHS Foundation Trust, or all of them as a file.
02

Study summary

In this study, investigators aim to study in detail the physical (including nutritional and pulmonary) and mental health of females with cystic fibrosis (CF) planning a pregnancy, during pregnancy, and in the early parenthood period.

Additionally the health of offspring in infancy and early life will be studied to understand if further screening investigations or clinical care models should be part of clinical guidelines

Read the detailed description

Improvements in treatments for people with CF have meant that more are becoming pregnant. CFTR modulators (CFTRm) are one of these treatments. They work by tackling the underlying cause of CF. These changes have created a need and an opportunity for research into the health and experiences of people with CF and their children in the CFTRm era.

The study is called 'MATRIARCH_CF' and includes 3 related sub-studies:

'Mama' is enrolling participants aged 16 years or older with CF under the care of the Royal Brompton Hospital (RBH) adult CF Unit who are planning a pregnancy or pregnant. The aim is to describe the impact of pregnancy and the first 12-24 months of parenthood in females with CF on their physical and psychological health. Investigations in eight visits include blood tests, lung function, imaging, and interviews.

'Mini' is enrolling biological offspring of people with CF (mothers and fathers) cared for by the RBH Adult CF Service, from birth to age two. The aim is to collect information that will allow for assessment of health outcomes in offspring of parents with CF in the short term. There will be up to four visits over two years with investigations including blood tests, sweat tests, and brain ultrasound.

'Midi' explores the same question as 'Mini' but in the longer term for those aged three-to-six. There will be up to two visits, and they include lung function testing and a lung MRI.

This study is described as 'observational' as investigators will not provide or change any treatment. Participant's health will be monitored with a range of investigations, many of which are optional. Knowledge gained from this study will be used to create guidelines to help families with CF and their medical teams make decisions around pregnancy and their offspring.

03

Conditions studied

  • Cystic Fibrosis (CF)
  • Pregnancy
  • Infant, Newborn
  • Exposure During Pregnancy

Browse trials for

Keywords

  • Pregnancy/obstetric health in women with cystic fibrosis
  • Pregnancy
  • CFTR modulators
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

  1. Females aged 16 years or older with CF under the care of the Royal Brompton Hospital adult CF Unit who are planning a pregnancy or pregnant.
  2. Biological offspring of people with CF (both mothers and fathers) cared for by the Royal Brompton Hospital Adult CF Service, from birth to aged six years.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

'Mama' sub-study:

  • Written obtained from participant.
  • Under the care of Royal Brompton Hospital CF Reproductive and Maternal Health Service
  • Age 16 years or above at time of recruitment
  • Confirmed diagnosis of CF
  • Planning a pregnancy or pregnant at time of recruitment.
  • Ability to adhere to the required visits and investigations.

'Mini' sub-study:

  • Written informed consent obtained from participant's legal guardian.
  • Infants who have one biological parent with a confirmed diagnosis of CF under care of Royal Brompton Hospital Adult CF Service
  • Less than 12 months of age at first visit.
  • Ability to adhere to the required visits and investigations.

'Midi' sub-study:

  • Written informed consent obtained from participant's legal guardian.
  • Children who have one biological parent with a confirmed diagnosis of CF who is under the care of Royal Brompton Hospital Adult CF Service.
  • Age three to six years at time of visit
  • Ability to adhere to the required visits and investigations.

Exclusion criteria

Exclusion Criteria:

'Mama' sub-study:

  • Any significant health condition which would cause inability to comply with protocol based on investigator discretion.
  • History of lung transplantation

'Mini' sub-study:

  • Legal guardians' inability to provide consent to participate in the study.
  • Mother of infant has significant comorbidities unrelated to CF which could affect infant outcomes based on investigator discretion.

'Midi' sub-study:

  • Legal guardians' inability to provide consent to participate in the study.
  • A significant health condition which is known to affect lung function or imaging based on investigator discretion
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Mama

    Females with Cystic Fibrosis who are pregnant or planning a pregnancy

  • Mini

    Children aged 0-24 months with one biological parent who has a diagnosis of cystic fibrosis

  • Midi

    Children aged 3-6 years with one biological parent who has a diagnosis of cystic fibrosis

06

What researchers measure

Primary outcomes

  1. Change in FEV1

    Change in FEV1 percent predicted (ppFEV1) from pre-conception/baseline to end of pregnancy, and at 12- and 24-months post-partum.

    Time frame: 9 months

  2. Incidence of CF-related pulmonary complications during pregnancy.

    Time frame: 9 months

  3. Incidence of premature delivery

    Defined as birth \<37 weeks gestation.

    Time frame: 3 years

  4. Frequency of liver dysfunction in infants

    Defined as ALT/AST/GGT/bilirubin above upper limit of normal using laboratory normal ranges. This is prospectively obtained in the 'Mini' sub-study, and retrospectively reviewed from medical records in the 'Midi' sub-study.

    Time frame: 2 years

  5. Incidence of congential abnormalities

    Based on medical history and examination

    Time frame: 3 years

  6. Frequency of CF diagnoses in infants despite negative newborn screen testing

    The number of participants with normal IRT subsequently diagnosed with CF (based on a combination of CF genetic tests, sweat chloride, and faecal elastase where appropriate).

    Time frame: 3 years

  7. Frequency of abnormal lung clearance index results in young children

    A lung clearance index (LCI) measurement above the normal levels as defined by investigating laboratory values (Midi only)

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Downes A, Bokobza I, Weitnauer L, Scott R, Dobra R, Short C, Semple T, Beaumont O, Williamson C, Davies JC, Felton I. Maternal, Infant, Reproductive and Child Health in Cystic Fibrosis (MATRIARCH_CF): a prospective, observational study to evaluate pregnancy and parenthood in females with cystic fibrosis and health of the offspring in the CFTR-modulator era. BMJ Open Respir Res. 2026 Jun 30;13(1):e004270. doi: 10.1136/bmjresp-2026-004270. PubMed 42379640 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Apr 2028, 34 months after the start.

Of 228 non-industry observational studies under Cystic Fibrosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 89. This study's planned 34 months is below that.

Counting every sponsor, half of 243 studies reached it within 41 months; a quarter within 19 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Jan 28, 2025
StartActual
Jun 12, 2025
Primary completionEst.
Apr 2028
CompletionEst.
May 2028
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06797206
Collaborators
Cystic Fibrosis Trust, King's College London, Imperial College London
Responsible party
Sponsor
First posted
Jan 28, 2025
Start date
Jun 12, 2025
Primary completion
Apr 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Oct 1, 2025

Study contacts

Amy Downes
Contact
a.downes@imperial.ac.uk
020 7352 8121 ext. 84935
Idan Bokobza
Contact
i.bokobza@imperial.ac.uk
Imogen Felton
principal investigator · Royal Brompton Hospital and NHLI Imperial College London
Jane Davies
principal investigator · Royal Brompton Hospital and NHLI Imperial College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion